Search results for " Cardiac"

showing 10 items of 523 documents

MicroRNA and receptor mediated signaling pathways as potential therapeutic targets in heart failure.

2016

Cardiac remodelling is a complex pathogenetic pathway involving genome expression, molecular, cellular, and interstitial changes that cause changes in size, shape and function of the heart after cardiac injury. Areas covered: We will review recent advances in understanding the role of several receptor-mediated signaling pathways and micro-RNAs, in addition to their potential as candidate target pathways in the pathogenesis of heart failure. The myocyte is the main target cell involved in the remodelling process via ischemia, cell necrosis and apoptosis (by means of various receptor pathways), and other mechanisms mediated by micro-RNAs. We will analyze the role of some receptor mediated sig…

0301 basic medicineheart failure target micro-RNA receptorSettore MED/09 - Medicina InternaClinical BiochemistryCellApoptosisBiology03 medical and health scienceschemistry.chemical_compoundGSK-3Drug DiscoverymicroRNAmedicineAnimalsHumansMyocytes CardiacAntagomirMolecular Targeted TherapyReceptorHeart FailurePharmacologyVentricular RemodelingReceptor-mediated endocytosisCell biologyMicroRNAs030104 developmental biologymedicine.anatomical_structurechemistryImmunologyMolecular MedicineSignal transductionSignal TransductionRelaxin receptor
researchProduct

High prevalence of arrhythmic and myocardial complications in patients with cardiac glycogenosis due to PRKAG2 mutations

2016

International audience; AIMS: Mutations in PRKAG2, the gene encoding for the γ2 subunit of 5'-AMP-activated protein kinase (AMPK), are responsible for an autosomal dominant glycogenosis with a cardiac presentation, associating hypertrophic cardiomyopathy (HCM), ventricular pre-excitation (VPE), and progressive heart block. The aim of this study was to perform a retrospective time-to-event study of the clinical manifestations associated with PRKAG2 mutations.METHODS AND RESULTS: A cohort of 34 patients from 9 families was recruited between 2001 and 2010. DNA were sequenced on all exons and flanking sequences of the PRKAG2 gene using Sanger sequencing. Overall, four families carried the recur…

0301 basic medicinemedicine.medical_specialtyHeart blockCardiomyopathymedicine.medical_treatmentCardiomyopathyDisease030204 cardiovascular system & hematologySudden cardiac deathTime-to-event study03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemPhysiology (medical)Internal medicineWolff–Parkinson–WhiteVentricular pre-excitationmedicineHeart transplantationbusiness.industryIncidence (epidemiology)Hypertrophic cardiomyopathy[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicine.diseasePRKAG23. Good health030104 developmental biologyCohortCardiologyCardiology and Cardiovascular Medicinebusiness
researchProduct

Cardiovascular disease in aging: an overview on thoracic aortic aneurysm as an emerging inflammatory disease

2017

Medial degeneration associated with thoracic aortic aneurysm and acute aortic dissection was originally described by Erdheim as a noninflammatory lesion related to the loss of smooth muscle cells and elastic fibre fragmentation in the media. Recent evidences propose the strong role of a chronic immune/inflammatory process in aneurysm evocation and progression. The coexistence of inflammatory cells with markers of apoptotic vascular cell death in the media of ascending aorta with aneurysms and type A dissections raises the possibility that activated T cells and macrophages may contribute to the elimination of smooth muscle cells and degradation of the matrix. On the other hand, several infla…

0301 basic medicinemedicine.medical_specialtyPathologyAgingImmunologyMyocytes Smooth MuscleThoracic aortic aneurysm; acute aortic dissection; inflammatory pathwayReview Article030204 cardiovascular system & hematologyThoracic aortic aneurysmLesion03 medical and health sciencesAortic aneurysm0302 clinical medicineAneurysmmedicine.arteryInternal medicineThoracic aortic aneurysmAscending aortamedicinelcsh:PathologySettore MED/05 - Patologia ClinicaMyocyteHumansAortic dissectionInflammationAortaacute aortic dissectionAortic Aneurysm Thoracicbusiness.industrySettore MED/23 - Chirurgia CardiacaCell Biologymedicine.diseaseinflammatory pathway030104 developmental biologyCardiovascular DiseasesCardiologycardiovascular systemmedicine.symptombusinesslcsh:RB1-214
researchProduct

Chronically elevated branched chain amino acid levels are pro-arrhythmic.

2022

Aim. Cardiac arrhythmias comprise a major health and economic burden and are associated with significant morbidity and mortality, including cardiac failure, stroke and sudden cardiac death (SCD). Development of efficient preventive and therapeutic strategies is hampered by incomplete knowledge of disease mechanisms and pathways. Our aim is to identify novel mechanisms underlying cardiac arrhythmia and SCD using an unbiased approach. Methods and Results. We employed a phenotype-driven N-ethyl-N-nitrosourea (ENU) mutagenesis screen and identified a mouse line with a high incidence of sudden death at young age (6-9 weeks) in the absence of prior symptoms. Affected mice were found to be homozyg…

0301 basic medicinemedicine.medical_specialtyPhysiologyBranched-chain amino acid030204 cardiovascular system & hematologySudden deathSudden cardiac deathAfterdepolarization03 medical and health scienceschemistry.chemical_compoundMice0302 clinical medicinePhysiology (medical)Internal medicineCardiac conductionmedicineAnimalsHumansMyocytes CardiacBCAAArrhythmia ; Bcaa ; Electrophysiology ; Metabolism ; Sudden DeathHeart FailureSirolimusbusiness.industrySudden deathCardiac arrhythmiamedicine.diseaseElectrophysiology030104 developmental biologyEndocrinologyMetabolismchemistryHeart failureCalciumMetabolic syndromeCardiology and Cardiovascular MedicinebusinessArrhythmiaAmino Acids Branched-ChainCardiovascular research
researchProduct

Hypoxie et régénération cardiaque : une nouvelle approche paradoxale de la cardioprotection

2017

IF 2.331; International audience

0301 basic medicinemedicine.medical_specialtyReactive oxygen species metabolismTranscription GeneticCardiac pathologyEnergy metabolismCardiac metabolismCardioprotectionHypoxie03 medical and health sciencesInternal medicinemedicineRégénérationAnimalsHumansRegenerationMyocytes CardiacTissue survivalHypoxiaCoeurCell ProliferationCardioprotectionHeart FailureTissue Survivalbusiness.industryOxygen metabolismHeartGeneral MedicineRecovery of FunctionHypoxia (medical)[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemCell HypoxiaOxygenOxidative Stress030104 developmental biologyGene Expression RegulationAnesthesiaCardiologymedicine.symptomCardiology and Cardiovascular MedicinebusinessEnergy MetabolismReactive Oxygen SpeciesSignal TransductionArchives of cardiovascular diseases
researchProduct

Systematic ajmaline challenge in patients with long QT 3 syndrome caused by the most common mutation: a multicentre study

2016

Aims Overlap syndromes of long QT 3 syndrome (LQT3) and the Brugada syndrome (BrS) have been reported. Identification of patients with an overlapping phenotype is crucial before initiation of Class I antiarrhythmic drugs for LQT3. Aim of the present study was to elucidate the yield of ajmaline challenge in unmasking the Brugada phenotype in patients with LQT3 caused by the most common mutation, SCN5A-E1784K. Methods and results Consecutive families in tertiary referral centres diagnosed with LQT3 caused by SCN5A-E1784K were included in the study. Besides routine clinical work-up, ajmaline challenge was performed after informed consent. A total of 23 subjects (11 female, mean age 27 ± 14 yea…

0301 basic medicinemedicine.medical_specialtymedicine.diagnostic_testbusiness.industryLong QT syndromeOverlap syndrome030204 cardiovascular system & hematologymedicine.diseaseSudden cardiac death03 medical and health sciencesAjmaline030104 developmental biology0302 clinical medicineEndocrinologyPhysiology (medical)Internal medicineMutation (genetic algorithm)medicineCardiologyFamily historyCardiology and Cardiovascular MedicinebusinessElectrocardiographyBrugada syndromemedicine.drugEP Europace
researchProduct

New insights about the putative role of myokines in the context of cardiac rehabilitation and secondary cardiovascular prevention.

2017

Exercise training prevents the onset and the development of many chronic diseases, acting as an effective tool both for primary and for secondary prevention. Various mechanisms that may be the effectors of these beneficial effects have been proposed during the past decades: some of these are well recognized, others less. Muscular myokines, released during and after muscular contraction, have been proposed as key mediators of the systemic effects of the exercise. Nevertheless the availability of an impressive amount of evidence regarding the systemic effects of muscle-derived factors, few studies have examined key issues: (I) if skeletal muscle cells themselves are the main source of cytokin…

0301 basic medicinemedicine.medical_specialtyregular exercisemedicine.medical_treatmentInflammationBioinformaticsCachexiaCoronary artery disease03 medical and health sciencesMyokineMyokineReview Article on Myokines Exercise and Cardiovascular DiseasemedicineRehabilitationMyokines; cardiac rehabilitation; cardiovascular disease (CVD); cerebrovascular disease; regular exercisecardiovascular disease (CVD)business.industrySkeletal muscleGeneral Medicinemedicine.diseasecerebrovascular diseasecardiac rehabilitation030104 developmental biologyCytokinemedicine.anatomical_structureSarcopeniaPhysical therapymedicine.symptombusiness
researchProduct

Fisioterapia en la fase de convalecencia: fase de esfuerzo

2010

Fisioterapia en la rehabilitación cardíaca: fase de convalecencia o fase II. En la sesión de entrenamiento, la fase de esfuerzo o endurecimiento pretende aumentar la capacidad funcional, la capacidad máxima de captación de oxígeno y la capacidad aeróbica máxima del paciente.

3213.11 Ciències MédiquesFisioterapia3213.11- Farmacia MedicinaFisioterapiarehabilitación cardiacacardiópatasejercicio físicofrecuencia cardíaca de entrenamientocasos clínicos
researchProduct

Fisioterapia en la fase de convalecencia: preparación

2010

Fisioterapia en la rehabilitación cardíaca: fase de convalecencia o fase II. Preparación del espacio y del paciente para realizar la sesión de entrenamiento.

3213.11 Ciències MédiquesFisioterapia3213.11- Farmacia MedicinaFisioterapiarehabilitación cardiacacardiópatasejercicio físicofrecuencia cardíaca de entrenamientocasos clínicos
researchProduct

Fisioterapia en la fase de convalecencia: enfriamiento

2010

Fisioterapia en la rehabilitación cardíaca: fase de convalecencia o fase II. La sesión de entrenamiento finaliza con la fase de enfriamiento o vuelta a la calma. Ésta pretende adaptar al paciente del esfuerzo al reposo, y evitar así respuestas tales como: la hipotensión y el mareo, y el control de posibles arritmias.

3213.11 Ciències MédiquesFisioterapia3213.11- Farmacia MedicinaFisioterapiarehabilitación cardiacacardiópatasejercicio físicofrecuencia cardíaca de entrenamientocasos clínicos
researchProduct